REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

February 27, 2024

https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-operational-highlights-302073278.html

ROCKVILLE, Md., Feb. 27, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights, including progress on the strategic pipeline prioritization and corporate restructuring intended to significantly reduce operating expenses and support meaningful value generation from the Company’s strong pipeline of AAV Therapeutics.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.